A Phase 2, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of GS-4774 for the Treatment of Virally Suppressed Subjects With Chronic Hepatitis B

Trial Profile

A Phase 2, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of GS-4774 for the Treatment of Virally Suppressed Subjects With Chronic Hepatitis B

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs GS 4774 (Primary)
  • Indications Hepatitis B
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Gilead Sciences
  • Most Recent Events

    • 19 May 2016 Results published in the Journal of Hepatology
    • 13 Nov 2015 Results from this trial will be presented at the Liver Meeting 2015, according to a GlobeImmune media release.
    • 27 May 2015 Primary endpoint (Mean change in log10 IU/mL serum hepatitis B surface antigen (HBsAg) from Baseline to Week 24) has not been met, according to a GlobeImmune media release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top